Catalyst Pharmaceuticals, Inc. (DELISTED) (CPRX:DL)
31.49
0.00 (0.00%)
USD |
NASDAQ |
Jul 24, 16:00
Catalyst Pharmaceuticals Enterprise Value : 3.094B for July 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| July 24, 2026 | 3.094B |
| July 23, 2026 | 3.094B |
| July 22, 2026 | 3.094B |
| July 21, 2026 | 3.094B |
| July 20, 2026 | 3.094B |
| July 17, 2026 | 3.094B |
| July 16, 2026 | 3.094B |
| July 15, 2026 | 3.094B |
| July 14, 2026 | 3.094B |
| July 13, 2026 | 3.093B |
| July 10, 2026 | 3.092B |
| July 09, 2026 | 3.092B |
| July 08, 2026 | 3.092B |
| July 07, 2026 | 3.094B |
| July 06, 2026 | 3.096B |
| July 02, 2026 | 3.089B |
| July 01, 2026 | 3.088B |
| June 30, 2026 | 3.087B |
| June 29, 2026 | 3.091B |
| June 26, 2026 | 3.096B |
| June 25, 2026 | 3.086B |
| June 24, 2026 | 3.086B |
| June 23, 2026 | 3.083B |
| June 22, 2026 | 3.081B |
| June 18, 2026 | 3.081B |
| Date | Value |
|---|---|
| June 17, 2026 | 3.083B |
| June 16, 2026 | 3.077B |
| June 15, 2026 | 3.080B |
| June 12, 2026 | 3.078B |
| June 11, 2026 | 3.080B |
| June 10, 2026 | 3.076B |
| June 09, 2026 | 3.076B |
| June 08, 2026 | 3.069B |
| June 05, 2026 | 3.067B |
| June 04, 2026 | 3.070B |
| June 03, 2026 | 3.069B |
| June 02, 2026 | 3.067B |
| June 01, 2026 | 3.067B |
| May 29, 2026 | 3.063B |
| May 28, 2026 | 3.070B |
| May 27, 2026 | 3.074B |
| May 26, 2026 | 3.075B |
| May 22, 2026 | 3.066B |
| May 21, 2026 | 3.069B |
| May 20, 2026 | 3.065B |
| May 19, 2026 | 3.060B |
| May 18, 2026 | 3.063B |
| May 15, 2026 | 3.056B |
| May 14, 2026 | 3.054B |
| May 13, 2026 | 3.054B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Inovio Pharmaceuticals, Inc. | 74.26M |
| Indivior Pharmaceuticals, Inc. | 4.556B |
| Exelixis, Inc. | 12.90B |
| United Therapeutics Corp. | 19.23B |
| Krystal Biotech, Inc. | 9.277B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 63.73M |
| Revenue (Quarterly) | 149.39M |
| Total Expenses (Quarterly) | 85.66M |
| EPS Diluted (Quarterly) | 0.5022 |
| Gross Profit Margin (Quarterly) | 83.82% |
| Profit Margin (Quarterly) | 42.66% |
| Earnings Yield | 5.52% |
| Operating Earnings Yield | 6.68% |
| Normalized Earnings Yield | 5.471 |